FY2025 EPS Estimates for CureVac Boosted by Leerink Partnrs

CureVac (NASDAQ:CVAC - Free Report) - Equities researchers at Leerink Partnrs boosted their FY2025 earnings estimates for shares of CureVac in a note issued to investors on Tuesday, May 20th. Leerink Partnrs analyst M. Foroohar now expects that the company will post earnings per share of ($0.68) for the year, up from their previous forecast of ($0.69). The consensus estimate for CureVac's current full-year earnings is $0.72 per share. Leerink Partnrs also issued estimates for CureVac's Q4 2025 earnings at ($0.08) EPS, FY2026 earnings at ($0.52) EPS and FY2027 earnings at ($0.34) EPS.

Several other brokerages also recently issued reports on CVAC. UBS Group cut their price target on CureVac from $13.00 to $12.00 and set a "buy" rating for the company in a report on Wednesday, April 30th. JMP Securities restated a "market outperform" rating and set a $16.00 target price on shares of CureVac in a research report on Friday, February 14th.

CureVac Stock Up 6.7%

NASDAQ:CVAC opened at $4.16 on Friday. CureVac has a twelve month low of $2.37 and a twelve month high of $5.28. The company has a quick ratio of 6.19, a current ratio of 6.20 and a debt-to-equity ratio of 0.05. The stock's 50 day moving average price is $3.22 and its two-hundred day moving average price is $3.28. The firm has a market capitalization of $933.25 million, a price-to-earnings ratio of 7.56 and a beta of 2.43.

CureVac (NASDAQ:CVAC - Get Free Report) last announced its earnings results on Thursday, May 22nd. The company reported ($0.24) earnings per share for the quarter, missing analysts' consensus estimates of ($0.16) by ($0.08). The company had revenue of $0.94 million during the quarter, compared to analyst estimates of $4.27 million. CureVac had a return on equity of 21.98% and a net margin of 20.72%.

Institutional Trading of CureVac

Several institutional investors have recently added to or reduced their stakes in the stock. GSA Capital Partners LLP acquired a new stake in CureVac in the first quarter worth $853,000. BNP Paribas Financial Markets purchased a new position in CureVac during the 4th quarter worth $585,000. Millennium Management LLC grew its position in CureVac by 10.3% in the 1st quarter. Millennium Management LLC now owns 1,816,984 shares of the company's stock worth $5,033,000 after purchasing an additional 169,947 shares in the last quarter. Two Sigma Investments LP bought a new position in shares of CureVac in the fourth quarter valued at approximately $391,000. Finally, State of Wyoming bought a new stake in CureVac during the first quarter worth $317,000. 17.26% of the stock is currently owned by institutional investors.

CureVac Company Profile

CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.